Moderna and Pfizer have previously announced that the updated vaccines would be ready this fall. The FDA’s approval comes amid a steady rise in reported COVID-19 cases and hospitalizations in ...

Moderna beat Wall Street's first-quarter expectations Thursday. The news could bolster Moderna stock, which is approaching ...

Here’s your go-to guide with everything you need to know about COVID-19, including testing expanding to more airports, ...

Booster shots help to "remind" it of how to respond to a virus ... for certain higher-risk individuals were also recommended. In September 2023, the FDA authorized Pfizer-BioNTech's updated vaccine ...

ORLANDO, Fla. (FNN) – Community advocate Cynthia Harris filed as a NPA candidate to run for the open Orange County Supervisor ...

The Delaware State Police continues to investigate the fatal pedestrian hit-and-run crash that occurred on Harbeson Road last ...

The Food and Drug Administration on Friday approved Pfizer’s treatment for a rare genetic bleeding disorder, making it the company’s first-ever gene therapy to win clearance in the U.S. The ...

Ten years after dipping its toes into the gene therapy pool in a licensing deal with Spark Therapeutics, Pfizer has gained FDA approval for the acquired treatment. The U.S. regulator has endorsed ...

Pfizer also seeks FDA approval for its experimental antibody, marstacimab, to treat hemophilia A and B. The company is also developing a gene therapy for Duchenne muscular dystrophy, a genetic ...

Pfizer said it will continue to monitor the long-term durability and safety of the gene therapy treatment over 15 years. Pfizer has set a list price for Beqvez at $3.5 million in the U.S. Beqvez ...

Pfizer (NYSE:PFE) said it has received FDA approval for its one-time gene therapy Beqvez for the treatment of certain adults with hemophilia B. The drugmaker said the therapy is aimed at enabling ...